Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Inclusion Criteria:

• A person who has been registered in the GV1001-PSP-CL2-011 clinical trial and hascompleted administration by Week 24

• A patient who accompanied all visits with the subject for the scheduled visit ofthis clinical trial, has a guardian who can supervise the subject's compliance withthe examination and examination procedures conducted at the time of the visit, andprovides information on the subject's indications, and whose guardian has agreed inwriting to participate in the clinical trial (except where it is unnecessary toaccompany the guardian at the discretion of the investigator)

• Patient and/or representative of the patient who has voluntarily agreed in writingto participate in this clinical trial

Exclusion Criteria:

• Patients deemed unsuitable by the investigator to participate in this extensionstudy

• Pregnant or male subjects who do not consent to contraception by medically approvedmethods (surgical infertility, intrauterine contraceptive devices, fallopian tubeligature, double blocking (combined use of male condoms, female condoms, cervicalcaps, contraceptive diaphragm and sponges) and 90 days after clinical trialparticipation However, women who have undergone menopause or surgical infertilityprocedures (such as vasectomy and difficult conception on both sides) beforeparticipating in clinical trials can participate without consent to contraception.

• Pregnant women or breastfeeding women